| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | TAP complex binding | 1.00e-11 | 9 | 50 | 5 | GO:0062061 | |
| GeneOntologyMolecularFunction | CD8 receptor binding | 1.00e-11 | 9 | 50 | 5 | GO:0042610 | |
| GeneOntologyMolecularFunction | TAP1 binding | 2.00e-11 | 10 | 50 | 5 | GO:0046978 | |
| GeneOntologyMolecularFunction | TAP2 binding | 2.00e-11 | 10 | 50 | 5 | GO:0046979 | |
| GeneOntologyMolecularFunction | TAP binding | 2.00e-11 | 10 | 50 | 5 | GO:0046977 | |
| GeneOntologyMolecularFunction | beta-2-microglobulin binding | 6.26e-11 | 12 | 50 | 5 | GO:0030881 | |
| GeneOntologyMolecularFunction | natural killer cell lectin-like receptor binding | 4.85e-10 | 17 | 50 | 5 | GO:0046703 | |
| GeneOntologyMolecularFunction | T cell receptor binding | 1.21e-09 | 20 | 50 | 5 | GO:0042608 | |
| GeneOntologyMolecularFunction | MHC class I protein binding | 1.53e-08 | 32 | 50 | 5 | GO:0042288 | |
| GeneOntologyMolecularFunction | 14-3-3 protein binding | 6.36e-08 | 42 | 50 | 5 | GO:0071889 | |
| GeneOntologyMolecularFunction | peptide antigen binding | 1.41e-07 | 49 | 50 | 5 | GO:0042605 | |
| GeneOntologyMolecularFunction | MHC protein binding | 3.32e-07 | 58 | 50 | 5 | GO:0042287 | |
| GeneOntologyMolecularFunction | peptide binding | 1.35e-05 | 318 | 50 | 7 | GO:0042277 | |
| GeneOntologyMolecularFunction | protein-folding chaperone binding | 5.06e-05 | 161 | 50 | 5 | GO:0051087 | |
| GeneOntologyMolecularFunction | antigen binding | 1.11e-04 | 190 | 50 | 5 | GO:0003823 | |
| GeneOntologyMolecularFunction | phosphoprotein binding | 3.14e-03 | 117 | 50 | 3 | GO:0051219 | |
| GeneOntologyMolecularFunction | ATP-dependent chromatin remodeler activity | 3.87e-03 | 37 | 50 | 2 | GO:0140658 | |
| GeneOntologyMolecularFunction | ATP-dependent activity, acting on DNA | 3.96e-03 | 127 | 50 | 3 | GO:0008094 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent | 5.14e-12 | 8 | 53 | 5 | GO:0002485 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent | 3.95e-10 | 16 | 53 | 5 | GO:0002486 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway | 5.58e-10 | 17 | 53 | 5 | GO:0002484 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class Ib | 5.58e-10 | 17 | 53 | 5 | GO:0002476 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen via MHC class Ib | 7.71e-10 | 18 | 53 | 5 | GO:0002428 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen via MHC class I | 7.71e-10 | 18 | 53 | 5 | GO:0042590 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen via MHC class I | 3.00e-09 | 23 | 53 | 5 | GO:0019885 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous peptide antigen | 4.72e-09 | 25 | 53 | 5 | GO:0002483 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation via MHC class Ib | 4.72e-09 | 25 | 53 | 5 | GO:0002475 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of endogenous antigen | 1.76e-08 | 32 | 53 | 5 | GO:0019883 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen via MHC class I | 6.45e-08 | 41 | 53 | 5 | GO:0002474 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell mediated cytotoxicity | 7.31e-08 | 42 | 53 | 5 | GO:0001916 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen | 1.45e-07 | 48 | 53 | 5 | GO:0002478 | |
| GeneOntologyBiologicalProcess | regulation of T cell mediated cytotoxicity | 2.41e-07 | 53 | 53 | 5 | GO:0001914 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous antigen | 3.82e-07 | 58 | 53 | 5 | GO:0019884 | |
| GeneOntologyBiologicalProcess | T cell mediated cytotoxicity | 9.85e-07 | 70 | 53 | 5 | GO:0001913 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell mediated immunity | 1.30e-06 | 74 | 53 | 5 | GO:0002711 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation of peptide antigen | 1.49e-06 | 76 | 53 | 5 | GO:0048002 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated cytotoxicity | 1.80e-06 | 79 | 53 | 5 | GO:0001912 | |
| GeneOntologyBiologicalProcess | vesicle cargo loading | 2.15e-06 | 36 | 53 | 4 | GO:0035459 | |
| GeneOntologyBiologicalProcess | positive regulation of cell killing | 3.08e-06 | 88 | 53 | 5 | GO:0031343 | |
| GeneOntologyBiologicalProcess | regulation of T cell mediated immunity | 9.63e-06 | 111 | 53 | 5 | GO:0002709 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 1.65e-05 | 124 | 53 | 5 | GO:0001910 | |
| GeneOntologyBiologicalProcess | antigen processing and presentation | 2.86e-05 | 139 | 53 | 5 | GO:0019882 | |
| GeneOntologyBiologicalProcess | regulation of cell killing | 3.74e-05 | 147 | 53 | 5 | GO:0031341 | |
| GeneOntologyBiologicalProcess | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 4.12e-05 | 150 | 53 | 5 | GO:0002824 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte mediated immunity | 4.12e-05 | 150 | 53 | 5 | GO:0002708 | |
| GeneOntologyBiologicalProcess | positive regulation of adaptive immune response | 5.44e-05 | 159 | 53 | 5 | GO:0002821 | |
| GeneOntologyBiologicalProcess | T cell mediated immunity | 6.12e-05 | 163 | 53 | 5 | GO:0002456 | |
| GeneOntologyBiologicalProcess | negative regulation of neuron projection development | 7.27e-05 | 169 | 53 | 5 | GO:0010977 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated immunity | 8.57e-05 | 175 | 53 | 5 | GO:0002705 | |
| GeneOntologyBiologicalProcess | leukocyte mediated cytotoxicity | 1.17e-04 | 187 | 53 | 5 | GO:0001909 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 1.48e-04 | 40 | 53 | 3 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 1.59e-04 | 41 | 53 | 3 | GO:0002716 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 2.10e-04 | 114 | 53 | 4 | GO:0045824 | |
| GeneOntologyBiologicalProcess | protection from natural killer cell mediated cytotoxicity | 2.31e-04 | 9 | 53 | 2 | GO:0042270 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 2.40e-04 | 47 | 53 | 3 | GO:0001911 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte mediated immunity | 3.19e-04 | 232 | 53 | 5 | GO:0002706 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 3.24e-04 | 52 | 53 | 3 | GO:0031342 | |
| GeneOntologyBiologicalProcess | negative regulation of cell projection organization | 3.25e-04 | 233 | 53 | 5 | GO:0031345 | |
| GeneOntologyBiologicalProcess | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 3.38e-04 | 235 | 53 | 5 | GO:0002822 | |
| GeneOntologyBiologicalProcess | multicellular organism growth | 4.41e-04 | 249 | 53 | 5 | GO:0035264 | |
| GeneOntologyBiologicalProcess | regulation of adaptive immune response | 4.65e-04 | 252 | 53 | 5 | GO:0002819 | |
| GeneOntologyBiologicalProcess | inner ear development | 4.74e-04 | 253 | 53 | 5 | GO:0048839 | |
| GeneOntologyBiologicalProcess | mRNA metabolic process | 4.97e-04 | 917 | 53 | 9 | GO:0016071 | |
| GeneOntologyBiologicalProcess | negative regulation of response to biotic stimulus | 6.12e-04 | 151 | 53 | 4 | GO:0002832 | |
| GeneOntologyBiologicalProcess | phosphatidylinositol phosphate biosynthetic process | 6.54e-04 | 66 | 53 | 3 | GO:0046854 | |
| GeneOntologyBiologicalProcess | endoplasmic reticulum to Golgi vesicle-mediated transport | 7.42e-04 | 159 | 53 | 4 | GO:0006888 | |
| GeneOntologyBiologicalProcess | ear development | 8.12e-04 | 285 | 53 | 5 | GO:0043583 | |
| GeneOntologyBiologicalProcess | regulation of neuron projection development | 9.23e-04 | 612 | 53 | 7 | GO:0010975 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 9.87e-04 | 76 | 53 | 3 | GO:0042269 | |
| GeneOntologyBiologicalProcess | cell killing | 1.13e-03 | 307 | 53 | 5 | GO:0001906 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 1.14e-03 | 80 | 53 | 3 | GO:0002715 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated immunity | 1.16e-03 | 309 | 53 | 5 | GO:0002703 | |
| GeneOntologyBiologicalProcess | detection of bacterium | 1.19e-03 | 20 | 53 | 2 | GO:0016045 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 1.27e-03 | 83 | 53 | 3 | GO:0002707 | |
| GeneOntologyBiologicalProcess | positive regulation of immune effector process | 1.30e-03 | 317 | 53 | 5 | GO:0002699 | |
| GeneOntologyBiologicalProcess | detection of other organism | 1.58e-03 | 23 | 53 | 2 | GO:0098543 | |
| GeneOntologyBiologicalProcess | RNA splicing | 1.76e-03 | 502 | 53 | 6 | GO:0008380 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 1.93e-03 | 96 | 53 | 3 | GO:0002704 | |
| GeneOntologyBiologicalProcess | negative regulation of defense response | 2.09e-03 | 353 | 53 | 5 | GO:0031348 | |
| GeneOntologyBiologicalProcess | mRNA splicing, via spliceosome | 2.22e-03 | 358 | 53 | 5 | GO:0000398 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 2.22e-03 | 358 | 53 | 5 | GO:0000377 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions | 2.33e-03 | 362 | 53 | 5 | GO:0000375 | |
| GeneOntologyCellularComponent | endoplasmic reticulum exit site | 1.06e-15 | 42 | 54 | 9 | GO:0070971 | |
| GeneOntologyCellularComponent | MHC class Ib protein complex | 1.99e-12 | 7 | 54 | 5 | GO:0032398 | |
| GeneOntologyCellularComponent | MHC class I protein complex | 2.37e-11 | 10 | 54 | 5 | GO:0042612 | |
| GeneOntologyCellularComponent | MHC class I peptide loading complex | 1.87e-10 | 14 | 54 | 5 | GO:0042824 | |
| GeneOntologyCellularComponent | cis-Golgi network membrane | 5.75e-10 | 17 | 54 | 5 | GO:0033106 | |
| GeneOntologyCellularComponent | Golgi medial cisterna | 3.09e-09 | 23 | 54 | 5 | GO:0005797 | |
| GeneOntologyCellularComponent | MHC protein complex | 6.01e-09 | 26 | 54 | 5 | GO:0042611 | |
| GeneOntologyCellularComponent | lumenal side of endoplasmic reticulum membrane | 2.91e-08 | 35 | 54 | 5 | GO:0098553 | |
| GeneOntologyCellularComponent | lumenal side of membrane | 1.50e-07 | 48 | 54 | 5 | GO:0098576 | |
| GeneOntologyCellularComponent | ER to Golgi transport vesicle membrane | 6.46e-07 | 64 | 54 | 5 | GO:0012507 | |
| GeneOntologyCellularComponent | phagocytic vesicle membrane | 2.37e-06 | 83 | 54 | 5 | GO:0030670 | |
| GeneOntologyCellularComponent | cis-Golgi network | 2.67e-06 | 85 | 54 | 5 | GO:0005801 | |
| GeneOntologyCellularComponent | endoplasmic reticulum membrane | UBXN4 PSEN2 HLA-A HLA-B HLA-C CTAGE8 HLA-F HLA-H CTAGE15 CTAGE6 CTAGE4 ATP10A MTDH KPNA2 | 3.50e-06 | 1293 | 54 | 14 | GO:0005789 |
| GeneOntologyCellularComponent | endoplasmic reticulum subcompartment | UBXN4 PSEN2 HLA-A HLA-B HLA-C CTAGE8 HLA-F HLA-H CTAGE15 CTAGE6 CTAGE4 ATP10A MTDH KPNA2 | 3.70e-06 | 1299 | 54 | 14 | GO:0098827 |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | UBXN4 PSEN2 HLA-A HLA-B HLA-C CTAGE8 HLA-F HLA-H CTAGE15 CTAGE6 CTAGE4 ATP10A MTDH KPNA2 | 4.74e-06 | 1327 | 54 | 14 | GO:0042175 |
| GeneOntologyCellularComponent | COPII-coated ER to Golgi transport vesicle | 9.48e-06 | 110 | 54 | 5 | GO:0030134 | |
| GeneOntologyCellularComponent | recycling endosome membrane | 1.04e-05 | 112 | 54 | 5 | GO:0055038 | |
| GeneOntologyCellularComponent | endocytic vesicle membrane | 1.74e-05 | 212 | 54 | 6 | GO:0030666 | |
| GeneOntologyCellularComponent | endoplasmic reticulum protein-containing complex | 1.76e-05 | 125 | 54 | 5 | GO:0140534 | |
| GeneOntologyCellularComponent | coated vesicle membrane | 1.89e-05 | 215 | 54 | 6 | GO:0030662 | |
| GeneOntologyCellularComponent | Golgi cisterna | 2.56e-05 | 135 | 54 | 5 | GO:0031985 | |
| GeneOntologyCellularComponent | phagocytic vesicle | 5.27e-05 | 157 | 54 | 5 | GO:0045335 | |
| GeneOntologyCellularComponent | Golgi stack | 7.90e-05 | 171 | 54 | 5 | GO:0005795 | |
| GeneOntologyCellularComponent | early endosome membrane | 2.16e-04 | 212 | 54 | 5 | GO:0031901 | |
| GeneOntologyCellularComponent | early endosome | 2.27e-04 | 481 | 54 | 7 | GO:0005769 | |
| GeneOntologyCellularComponent | recycling endosome | 2.67e-04 | 222 | 54 | 5 | GO:0055037 | |
| GeneOntologyCellularComponent | coated vesicle | 3.22e-04 | 360 | 54 | 6 | GO:0030135 | |
| GeneOntologyCellularComponent | transport vesicle | 3.60e-04 | 519 | 54 | 7 | GO:0030133 | |
| GeneOntologyCellularComponent | endocytic vesicle | 4.53e-04 | 384 | 54 | 6 | GO:0030139 | |
| GeneOntologyCellularComponent | Golgi membrane | 4.93e-04 | 721 | 54 | 8 | GO:0000139 | |
| GeneOntologyCellularComponent | CHD-type complex | 8.69e-04 | 17 | 54 | 2 | GO:0090545 | |
| GeneOntologyCellularComponent | NuRD complex | 8.69e-04 | 17 | 54 | 2 | GO:0016581 | |
| GeneOntologyCellularComponent | transport vesicle membrane | 9.43e-04 | 293 | 54 | 5 | GO:0030658 | |
| GeneOntologyCellularComponent | Golgi apparatus subcompartment | 9.57e-04 | 443 | 54 | 6 | GO:0098791 | |
| GeneOntologyCellularComponent | histone deacetylase complex | 1.39e-03 | 85 | 54 | 3 | GO:0000118 | |
| GeneOntologyCellularComponent | membrane raft | 2.39e-03 | 362 | 54 | 5 | GO:0045121 | |
| GeneOntologyCellularComponent | membrane microdomain | 2.45e-03 | 364 | 54 | 5 | GO:0098857 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | 2.49e-03 | 1377 | 54 | 10 | GO:0140513 | |
| GeneOntologyCellularComponent | endosome membrane | 4.45e-03 | 602 | 54 | 6 | GO:0010008 | |
| GeneOntologyCellularComponent | cytoplasmic ribonucleoprotein granule | 5.12e-03 | 269 | 54 | 4 | GO:0036464 | |
| GeneOntologyCellularComponent | ribonucleoprotein granule | 6.42e-03 | 287 | 54 | 4 | GO:0035770 | |
| GeneOntologyCellularComponent | lysosomal membrane | 6.71e-03 | 462 | 54 | 5 | GO:0005765 | |
| GeneOntologyCellularComponent | lytic vacuole membrane | 6.71e-03 | 462 | 54 | 5 | GO:0098852 | |
| GeneOntologyCellularComponent | endosome | 9.73e-03 | 1167 | 54 | 8 | GO:0005768 | |
| GeneOntologyCellularComponent | vacuolar membrane | 9.80e-03 | 507 | 54 | 5 | GO:0005774 | |
| GeneOntologyCellularComponent | secretory granule membrane | 1.03e-02 | 329 | 54 | 4 | GO:0030667 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 1.08e-02 | 519 | 54 | 5 | GO:0009897 | |
| MousePheno | spinal cord inflammation | 9.38e-12 | 8 | 41 | 5 | MP:0030987 | |
| MousePheno | decreased immature NK cell number | 6.24e-08 | 14 | 41 | 4 | MP:0013666 | |
| MousePheno | decreased susceptibility to autoimmune diabetes | 1.89e-07 | 45 | 41 | 5 | MP:0004804 | |
| MousePheno | decreased mature NK cell number | 1.89e-07 | 18 | 41 | 4 | MP:0013672 | |
| MousePheno | abnormal immature NK cell number | 2.39e-07 | 19 | 41 | 4 | MP:0013665 | |
| MousePheno | abnormal immature NK cell morphology | 2.39e-07 | 19 | 41 | 4 | MP:0013699 | |
| MousePheno | cystolithiasis | 4.48e-07 | 22 | 41 | 4 | MP:0011625 | |
| MousePheno | CNS inflammation | 4.80e-07 | 54 | 41 | 5 | MP:0006082 | |
| MousePheno | abnormal mature NK cell number | 6.49e-07 | 24 | 41 | 4 | MP:0013671 | |
| MousePheno | abnormal mature NK cell morphology | 7.70e-07 | 25 | 41 | 4 | MP:0013700 | |
| MousePheno | urolithiasis | 1.89e-06 | 31 | 41 | 4 | MP:0005360 | |
| MousePheno | demyelination | 4.66e-06 | 85 | 41 | 5 | MP:0000921 | |
| MousePheno | decreased gamma-delta T cell number | 1.04e-05 | 47 | 41 | 4 | MP:0008347 | |
| MousePheno | decreased CD8-positive, alpha-beta T cell number | 3.83e-05 | 218 | 41 | 6 | MP:0008079 | |
| MousePheno | abnormal gamma-delta T cell number | 4.80e-05 | 69 | 41 | 4 | MP:0008345 | |
| MousePheno | increased T cell number | 5.96e-05 | 475 | 41 | 8 | MP:0005015 | |
| MousePheno | increased CD4-positive, alpha-beta T cell number | 6.69e-05 | 241 | 41 | 6 | MP:0008074 | |
| MousePheno | abnormal gamma-delta T cell morphology | 7.77e-05 | 78 | 41 | 4 | MP:0008343 | |
| MousePheno | increased NK cell number | 9.44e-05 | 82 | 41 | 4 | MP:0008044 | |
| MousePheno | abnormal myelination | 1.18e-04 | 166 | 41 | 5 | MP:0000920 | |
| MousePheno | abnormal CD4-positive, alpha-beta T cell number | 1.25e-04 | 391 | 41 | 7 | MP:0008073 | |
| MousePheno | decreased susceptibility to autoimmune disorder | 1.72e-04 | 180 | 41 | 5 | MP:0005351 | |
| MousePheno | abnormal CD4-positive, alpha beta T cell morphology | 2.49e-04 | 437 | 41 | 7 | MP:0002432 | |
| MousePheno | abnormal T cell activation | 2.70e-04 | 311 | 41 | 6 | MP:0001828 | |
| MousePheno | increased alpha-beta T cell number | 2.70e-04 | 311 | 41 | 6 | MP:0012764 | |
| MousePheno | decreased alpha-beta T cell number | 2.89e-04 | 315 | 41 | 6 | MP:0012765 | |
| MousePheno | decreased NK cell number | 4.09e-04 | 120 | 41 | 4 | MP:0008045 | |
| MousePheno | abnormal CD8-positive, alpha-beta T cell number | 5.22e-04 | 352 | 41 | 6 | MP:0008077 | |
| MousePheno | abnormal leukocyte physiology | IL10RA MLKL HLA-A HLA-B HLA-C JMJD6 DHRS4L1 PI4KA HLA-F HLA-H MTDH ITPKB | 5.70e-04 | 1425 | 41 | 12 | MP:0002442 |
| MousePheno | abnormal immune cell physiology | IL10RA MLKL HLA-A HLA-B HLA-C JMJD6 DHRS4L1 PI4KA HLA-F HLA-H MTDH ITPKB | 6.68e-04 | 1450 | 41 | 12 | MP:0001819 |
| MousePheno | abnormal cell-mediated immunity | IL10RA MLKL HLA-A HLA-B HLA-C JMJD6 DHRS4L1 PI4KA HLA-F HLA-H MTDH ITPKB | 7.24e-04 | 1463 | 41 | 12 | MP:0002421 |
| MousePheno | abnormal urinary bladder morphology | 7.37e-04 | 247 | 41 | 5 | MP:0000538 | |
| MousePheno | abnormal CD8-positive, alpha beta T cell morphology | 7.69e-04 | 379 | 41 | 6 | MP:0005010 | |
| MousePheno | abnormal adaptive immunity | IL10RA MLKL HLA-A HLA-B HLA-C JMJD6 DHRS4L1 PI4KA HLA-F HLA-H MTDH ITPKB | 8.53e-04 | 1490 | 41 | 12 | MP:0002420 |
| MousePheno | abnormal circulating interleukin-1 alpha level | 8.60e-04 | 15 | 41 | 2 | MP:0008637 | |
| MousePheno | abnormal alpha-beta T cell number | 9.05e-04 | 542 | 41 | 7 | MP:0012763 | |
| MousePheno | autoimmune response | 9.92e-04 | 398 | 41 | 6 | MP:0001844 | |
| MousePheno | abnormal self tolerance | 1.02e-03 | 400 | 41 | 6 | MP:0005005 | |
| MousePheno | abnormal immune tolerance | 1.07e-03 | 404 | 41 | 6 | MP:0005000 | |
| MousePheno | abnormal circulating interleukin-1 level | 1.37e-03 | 75 | 41 | 3 | MP:0008589 | |
| MousePheno | abnormal hemoglobin | TMPRSS15 LATS1 TRANK1 PSEN2 ZC3H13 HLA-F GIGYF2 ANAPC7 SLC6A14 | 1.40e-03 | 946 | 41 | 9 | MP:0001588 |
| MousePheno | abnormal NK cell number | 1.57e-03 | 172 | 41 | 4 | MP:0008043 | |
| Domain | MHC_I_a_C | 6.70e-13 | 6 | 50 | 5 | IPR010579 | |
| Domain | MHC_I_C | 6.70e-13 | 6 | 50 | 5 | PF06623 | |
| Domain | MHC_I | 2.21e-09 | 21 | 50 | 5 | PF00129 | |
| Domain | MHC_I_a_a1/a2 | 2.21e-09 | 21 | 50 | 5 | IPR001039 | |
| Domain | C1-set | 3.21e-07 | 54 | 50 | 5 | PF07654 | |
| Domain | IGc1 | 3.86e-07 | 56 | 50 | 5 | SM00407 | |
| Domain | Ig_C1-set | 4.61e-07 | 58 | 50 | 5 | IPR003597 | |
| Domain | Ig/MHC_CS | 4.61e-07 | 58 | 50 | 5 | IPR003006 | |
| Domain | - | 4.64e-07 | 24 | 50 | 4 | 3.30.500.10 | |
| Domain | MHC_I-like_Ag-recog | 4.64e-07 | 24 | 50 | 4 | IPR011161 | |
| Domain | IG_MHC | 5.47e-07 | 60 | 50 | 5 | PS00290 | |
| Domain | MHC_I/II-like_Ag-recog | 3.14e-06 | 38 | 50 | 4 | IPR011162 | |
| Domain | MAM_1 | 9.86e-06 | 16 | 50 | 3 | PS00740 | |
| Domain | MAM | 1.20e-05 | 17 | 50 | 3 | SM00137 | |
| Domain | MAM | 1.43e-05 | 18 | 50 | 3 | PF00629 | |
| Domain | MAM_dom | 1.43e-05 | 18 | 50 | 3 | IPR000998 | |
| Domain | MAM_2 | 1.43e-05 | 18 | 50 | 3 | PS50060 | |
| Domain | CHDCT2 | 2.10e-05 | 3 | 50 | 2 | PF08074 | |
| Domain | CHDNT | 2.10e-05 | 3 | 50 | 2 | PF08073 | |
| Domain | DUF1086 | 2.10e-05 | 3 | 50 | 2 | IPR009462 | |
| Domain | DUF1087 | 2.10e-05 | 3 | 50 | 2 | IPR009463 | |
| Domain | CHD_N | 2.10e-05 | 3 | 50 | 2 | IPR012958 | |
| Domain | CHD_C2 | 2.10e-05 | 3 | 50 | 2 | IPR012957 | |
| Domain | DUF1087 | 2.10e-05 | 3 | 50 | 2 | PF06465 | |
| Domain | DUF1086 | 2.10e-05 | 3 | 50 | 2 | PF06461 | |
| Domain | DUF1087 | 2.10e-05 | 3 | 50 | 2 | SM01147 | |
| Domain | DUF1086 | 2.10e-05 | 3 | 50 | 2 | SM01146 | |
| Domain | PI3/4_kinase_CS | 7.21e-04 | 15 | 50 | 2 | IPR018936 | |
| Domain | - | 8.23e-04 | 16 | 50 | 2 | 1.10.1070.11 | |
| Domain | PI3Kc | 8.23e-04 | 16 | 50 | 2 | SM00146 | |
| Domain | PI3/4_kinase_cat_dom | 1.05e-03 | 18 | 50 | 2 | IPR000403 | |
| Domain | PI3_PI4_kinase | 1.05e-03 | 18 | 50 | 2 | PF00454 | |
| Domain | PI3_4_KINASE_3 | 1.05e-03 | 18 | 50 | 2 | PS50290 | |
| Domain | PI3_4_KINASE_1 | 1.05e-03 | 18 | 50 | 2 | PS00915 | |
| Domain | PI3_4_KINASE_2 | 1.05e-03 | 18 | 50 | 2 | PS00916 | |
| Domain | Chromo_domain | 1.87e-03 | 24 | 50 | 2 | IPR023780 | |
| Domain | IG_LIKE | 1.91e-03 | 491 | 50 | 6 | PS50835 | |
| Domain | Ig-like_dom | 2.16e-03 | 503 | 50 | 6 | IPR007110 | |
| Domain | Chromo | 2.19e-03 | 26 | 50 | 2 | PF00385 | |
| Domain | CHROMO_1 | 2.54e-03 | 28 | 50 | 2 | PS00598 | |
| Domain | CHROMO_2 | 2.54e-03 | 28 | 50 | 2 | PS50013 | |
| Domain | Ig-like_fold | 2.60e-03 | 706 | 50 | 7 | IPR013783 | |
| Domain | SNF2_N | 3.31e-03 | 32 | 50 | 2 | IPR000330 | |
| Domain | Chromodomain-like | 3.31e-03 | 32 | 50 | 2 | IPR016197 | |
| Domain | SNF2_N | 3.31e-03 | 32 | 50 | 2 | PF00176 | |
| Domain | Chromo/shadow_dom | 3.52e-03 | 33 | 50 | 2 | IPR000953 | |
| Domain | CHROMO | 3.52e-03 | 33 | 50 | 2 | SM00298 | |
| Domain | DNA/RNA_helicase_DEAH_CS | 3.95e-03 | 35 | 50 | 2 | IPR002464 | |
| Domain | UBA | 4.18e-03 | 36 | 50 | 2 | PF00627 | |
| Domain | - | 4.33e-03 | 248 | 50 | 4 | 1.25.40.20 | |
| Domain | ANK | 4.52e-03 | 251 | 50 | 4 | SM00248 | |
| Domain | DEAH_ATP_HELICASE | 4.64e-03 | 38 | 50 | 2 | PS00690 | |
| Domain | ANK_REPEAT | 4.65e-03 | 253 | 50 | 4 | PS50088 | |
| Domain | Ankyrin_rpt-contain_dom | 4.71e-03 | 254 | 50 | 4 | IPR020683 | |
| Domain | ANK_REP_REGION | 4.71e-03 | 254 | 50 | 4 | PS50297 | |
| Domain | - | 5.13e-03 | 40 | 50 | 2 | 4.10.1000.10 | |
| Domain | Ankyrin_rpt | 5.26e-03 | 262 | 50 | 4 | IPR002110 | |
| Domain | UBA | 6.18e-03 | 44 | 50 | 2 | IPR015940 | |
| Domain | UBA | 7.03e-03 | 47 | 50 | 2 | PS50030 | |
| Domain | ZnF_C3H1 | 7.32e-03 | 48 | 50 | 2 | SM00356 | |
| Domain | zf-CCCH | 7.62e-03 | 49 | 50 | 2 | PF00642 | |
| Pathway | REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY | 1.18e-11 | 9 | 37 | 5 | MM14527 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_KSHV_MIR1_2_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 6.00e-10 | 6 | 37 | 4 | M47468 | |
| Pathway | REACTOME_ER_PHAGOSOME_PATHWAY | 7.86e-10 | 18 | 37 | 5 | MM14525 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HTLV_1_P12_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 1.40e-09 | 7 | 37 | 4 | M47582 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 1.40e-09 | 7 | 37 | 4 | M47530 | |
| Pathway | BIOCARTA_CTL_PATHWAY | 1.42e-09 | 20 | 37 | 5 | MM1374 | |
| Pathway | BIOCARTA_NKCELLS_PATHWAY | 4.81e-09 | 25 | 37 | 5 | MM1465 | |
| Pathway | REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC | 4.81e-09 | 25 | 37 | 5 | MM15713 | |
| Pathway | REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY | 1.31e-08 | 11 | 37 | 4 | M525 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ANTIGEN_PROCESSING_AND_PRESENTATION_BY_MHC_CLASS_I_MOLECULES | 1.96e-08 | 12 | 37 | 4 | M47529 | |
| Pathway | REACTOME_DAP12_INTERACTIONS | 2.71e-07 | 54 | 37 | 5 | MM14871 | |
| Pathway | REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC | 9.10e-07 | 29 | 37 | 4 | M1062 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 1.52e-06 | 76 | 37 | 5 | MM14526 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 1.73e-06 | 78 | 37 | 5 | M973 | |
| Pathway | KEGG_ALLOGRAFT_REJECTION | 2.49e-06 | 37 | 37 | 4 | M18615 | |
| Pathway | KEGG_GRAFT_VERSUS_HOST_DISEASE | 3.79e-06 | 41 | 37 | 4 | M13519 | |
| Pathway | KEGG_TYPE_I_DIABETES_MELLITUS | 4.61e-06 | 43 | 37 | 4 | M12617 | |
| Pathway | REACTOME_INTERFERON_GAMMA_SIGNALING | 5.35e-06 | 98 | 37 | 5 | M965 | |
| Pathway | KEGG_AUTOIMMUNE_THYROID_DISEASE | 9.94e-06 | 52 | 37 | 4 | M13103 | |
| Pathway | WP_PROTEASOME_DEGRADATION | 1.34e-05 | 56 | 37 | 4 | MM15901 | |
| Pathway | REACTOME_SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES | 1.83e-05 | 126 | 37 | 5 | M45009 | |
| Pathway | WP_PROTEASOME_DEGRADATION | 2.01e-05 | 62 | 37 | 4 | M39639 | |
| Pathway | WP_TAR_SYNDROME | 2.14e-05 | 63 | 37 | 4 | M48082 | |
| Pathway | KEGG_CELL_ADHESION_MOLECULES_CAMS | 2.37e-05 | 133 | 37 | 5 | M16476 | |
| Pathway | REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL | 2.55e-05 | 135 | 37 | 5 | MM14781 | |
| Pathway | KEGG_VIRAL_MYOCARDITIS | 3.25e-05 | 70 | 37 | 4 | M12294 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 7.01e-05 | 273 | 37 | 6 | M983 | |
| Pathway | KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 8.00e-05 | 88 | 37 | 4 | M16004 | |
| Pathway | WP_ALLOGRAFT_REJECTION | 8.36e-05 | 89 | 37 | 4 | M39398 | |
| Pathway | REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION | 1.65e-04 | 106 | 37 | 4 | M518 | |
| Pathway | REACTOME_SARS_COV_2_HOST_INTERACTIONS | 1.81e-04 | 204 | 37 | 5 | M45011 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 2.44e-04 | 343 | 37 | 6 | MM15712 | |
| Pathway | WP_EBOLA_VIRUS_INFECTION_IN_HOST | 3.50e-04 | 129 | 37 | 4 | M39693 | |
| Pathway | REACTOME_SARS_COV_2_INFECTION | 1.04e-03 | 299 | 37 | 5 | M41727 | |
| Pathway | KEGG_ENDOCYTOSIS | 1.25e-03 | 181 | 37 | 4 | M1519 | |
| Pathway | REACTOME_SARS_COV_INFECTIONS | 1.30e-03 | 471 | 37 | 6 | M39009 | |
| Pathway | REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL | 1.49e-03 | 190 | 37 | 4 | M8240 | |
| Pathway | REACTOME_NEUTROPHIL_DEGRANULATION | 1.97e-03 | 511 | 37 | 6 | MM15330 | |
| Pathway | REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION | 3.00e-03 | 381 | 37 | 5 | M1066 | |
| Pathway | REACTOME_NUCLEAR_EVENTS_STIMULATED_BY_ALK_SIGNALING_IN_CANCER | 3.78e-03 | 35 | 37 | 2 | M42525 | |
| Pathway | REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | 3.95e-03 | 789 | 37 | 7 | M1060 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 6088985 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 1686840 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 1705528 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 2808323 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 21088134 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 34181639 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 69663 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 8206527 | ||
| Pubmed | Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. | 1.56e-13 | 7 | 54 | 5 | 12459592 | |
| Pubmed | Multiple sequences related to classical histocompatibility antigens in the mouse genome. | 1.56e-13 | 7 | 54 | 5 | 6264319 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3456611 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 15809355 | ||
| Pubmed | Sequence analysis of the C3H H-2K1k gene: relationship to the H-2 loci. | 1.56e-13 | 7 | 54 | 5 | 2714856 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 10500200 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16210630 | ||
| Pubmed | Structural analysis of H-2Kf and H-2Kfm1 by using H-2K locus-specific sequences. | 1.56e-13 | 7 | 54 | 5 | 2391419 | |
| Pubmed | Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA TL+ and TL- strains. | 1.56e-13 | 7 | 54 | 5 | 3840195 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 15671142 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 14215561 | ||
| Pubmed | Tolerance and MHC restriction in transgenic mice expressing a MHC class I gene in erythroid cells. | 1.56e-13 | 7 | 54 | 5 | 1540549 | |
| Pubmed | Mouse histocompatibility genes: structure and organisation of a Kd gene. | 1.56e-13 | 7 | 54 | 5 | 11894934 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 19700752 | ||
| Pubmed | A saturation hypothesis to explain both enhanced and impaired learning with enhanced plasticity. | 1.56e-13 | 7 | 54 | 5 | 28234229 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 11894963 | ||
| Pubmed | Interaction of H-2Db with mutant histocompatibility gene H (KH-11) in the mouse. | 1.56e-13 | 7 | 54 | 5 | 6242891 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16836618 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 22287714 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 17512611 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3997208 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3263465 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 7018573 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 2997361 | ||
| Pubmed | Expression of GM1 and GD1a in mouse liver is linked to the H-2 complex on chromosome 17. | 1.56e-13 | 7 | 54 | 5 | 6671979 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 18974374 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 9869916 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16148128 | ||
| Pubmed | The role of the MHC on resistance to group a streptococci in mice. | 1.56e-13 | 7 | 54 | 5 | 16148132 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 312902 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 2642506 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 9037062 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 1840571 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16476767 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16148097 | ||
| Pubmed | Serological analysis of H-2 mutations using monoclonal antibodies. | 1.56e-13 | 7 | 54 | 5 | 6084033 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 20957233 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 11580250 | ||
| Pubmed | V beta T cell repertoire of CD8+ splenocytes selected on nonpolymorphic MHC class I molecules. | 1.56e-13 | 7 | 54 | 5 | 11086076 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 24101547 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12682111 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3335396 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12750360 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 6689056 | ||
| Pubmed | The multi-locus H-2Dw16 region has an organization distinct from the Dd region. | 1.56e-13 | 7 | 54 | 5 | 1348492 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 16461341 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 18416856 | ||
| Pubmed | Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire. | 1.56e-13 | 7 | 54 | 5 | 20974936 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 10704462 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 6895187 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 22573867 | ||
| Pubmed | Genetic control of corticosteroid side-chain isomerase activity in the mouse. | 1.56e-13 | 7 | 54 | 5 | 6822218 | |
| Pubmed | A novel H-2K splice form: predictions for other alternative H-2 splicing events. | 1.56e-13 | 7 | 54 | 5 | 2908875 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 15210799 | ||
| Pubmed | Comparison of exon 5 sequences from 35 class I genes of the BALB/c mouse. | 1.56e-13 | 7 | 54 | 5 | 2584927 | |
| Pubmed | Studies of two H-2Db mutants: B6. C-H-2bm13 and B6.C-H-2bm14. | 1.56e-13 | 7 | 54 | 5 | 6159320 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3496275 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12147629 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3458188 | ||
| Pubmed | NK gene complex and chromosome 19 loci enhance MHC resistance to murine cytomegalovirus infection. | 1.56e-13 | 7 | 54 | 5 | 19820922 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 19462379 | ||
| Pubmed | Structural diversity of the classical H-2 genes: K, D, and L. | 1.56e-13 | 7 | 54 | 5 | 1730883 | |
| Pubmed | Synapse elimination and learning rules co-regulated by MHC class I H2-Db. | 1.56e-13 | 7 | 54 | 5 | 24695230 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 8181071 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3680952 | ||
| Pubmed | Thymus leukemia antigen controls intraepithelial lymphocyte function and inflammatory bowel disease. | 1.56e-13 | 7 | 54 | 5 | 19004778 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 6300887 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 23142461 | ||
| Pubmed | Structure of C-terminal half of two H-2 antigens from cloned mRNA. | 1.56e-13 | 7 | 54 | 5 | 6895103 | |
| Pubmed | H-2-linked regulation of xenotropic murine leukemia virus expression. | 1.56e-13 | 7 | 54 | 5 | 6300850 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3094964 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 8500526 | ||
| Pubmed | The nucleotide sequence and comparative analysis of the H-2Dp class I H-2 gene. | 1.56e-13 | 7 | 54 | 5 | 3082989 | |
| Pubmed | Expression of H-2K and H-2D genes by PYS-2 teratocarcinoma cells. | 1.56e-13 | 7 | 54 | 5 | 3202874 | |
| Pubmed | cDNA clone coding for part of a mouse H-2d major histocompatibility antigen. | 1.56e-13 | 7 | 54 | 5 | 6265910 | |
| Pubmed | Cutting edge: MHC class I-Ly49 interaction regulates neuronal function. | 1.56e-13 | 7 | 54 | 5 | 18453559 | |
| Pubmed | DNA polymorphisms defined by the Tu108 probe map to the Tla region of mouse chromosome 17. | 1.56e-13 | 7 | 54 | 5 | 2906539 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 7675041 | ||
| Pubmed | Nucleotide sequences of H2g7 K and D loci of nonobese diabetic mice. | 1.56e-13 | 7 | 54 | 5 | 7759137 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3013627 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 6799575 | ||
| Pubmed | Qa antigen expression on functional lymphoid, myeloid, and stem cells in adult mice. | 1.56e-13 | 7 | 54 | 5 | 6966299 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12140378 | ||
| Pubmed | Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. | 1.56e-13 | 7 | 54 | 5 | 11854356 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 2410925 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 11842259 | ||
| Pubmed | DNA sequence of the mouse H-2Dd transplantation antigen gene. | 1.56e-13 | 7 | 54 | 5 | 3856254 | |
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12421934 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3894562 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 27385590 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 3840763 | ||
| Pubmed | 1.56e-13 | 7 | 54 | 5 | 12421940 | ||
| Interaction | CTAGE1 interactions | 9.55e-09 | 10 | 54 | 4 | int:CTAGE1 | |
| Interaction | LILRB1 interactions | 9.55e-09 | 10 | 54 | 4 | int:LILRB1 | |
| Interaction | LILRB2 interactions | 9.55e-09 | 10 | 54 | 4 | int:LILRB2 | |
| Interaction | HLA-E interactions | 2.22e-06 | 79 | 54 | 5 | int:HLA-E | |
| Interaction | CCDC8 interactions | 8.18e-06 | 656 | 54 | 10 | int:CCDC8 | |
| Interaction | HLA-H interactions | 1.20e-05 | 17 | 54 | 3 | int:HLA-H | |
| Interaction | ADNP2 interactions | 1.32e-05 | 54 | 54 | 4 | int:ADNP2 | |
| Interaction | ATP2A1 interactions | 1.58e-05 | 423 | 54 | 8 | int:ATP2A1 | |
| Interaction | HLA-G interactions | 1.59e-05 | 118 | 54 | 5 | int:HLA-G | |
| Interaction | HLA-DRB3 interactions | 3.11e-05 | 67 | 54 | 4 | int:HLA-DRB3 | |
| Interaction | DNAJC16 interactions | 3.64e-05 | 233 | 54 | 6 | int:DNAJC16 | |
| Interaction | CD1A interactions | 4.14e-05 | 72 | 54 | 4 | int:CD1A | |
| Interaction | CLEC4E interactions | 4.16e-05 | 353 | 54 | 7 | int:CLEC4E | |
| Interaction | HLA-B interactions | 4.19e-05 | 239 | 54 | 6 | int:HLA-B | |
| Interaction | CD8A interactions | 4.53e-05 | 26 | 54 | 3 | int:CD8A | |
| Interaction | CD1B interactions | 5.39e-05 | 77 | 54 | 4 | int:CD1B | |
| Interaction | HLA-DQB1 interactions | 6.90e-05 | 82 | 54 | 4 | int:HLA-DQB1 | |
| Interaction | KIR3DL3 interactions | 7.01e-05 | 30 | 54 | 3 | int:KIR3DL3 | |
| Interaction | OGFOD3 interactions | 8.54e-05 | 32 | 54 | 3 | int:OGFOD3 | |
| Interaction | B2M interactions | 1.08e-04 | 92 | 54 | 4 | int:B2M | |
| Interaction | DNAJC25 interactions | 1.09e-04 | 284 | 54 | 6 | int:DNAJC25 | |
| Interaction | TMPRSS11B interactions | 1.16e-04 | 416 | 54 | 7 | int:TMPRSS11B | |
| Interaction | RHOC interactions | 1.52e-04 | 584 | 54 | 8 | int:RHOC | |
| Interaction | RND2 interactions | 1.65e-04 | 440 | 54 | 7 | int:RND2 | |
| Interaction | CSNK2A3 interactions | 2.15e-04 | 110 | 54 | 4 | int:CSNK2A3 | |
| Interaction | MIA2 interactions | 2.39e-04 | 113 | 54 | 4 | int:MIA2 | |
| Interaction | ZRSR2P1 interactions | 2.51e-04 | 9 | 54 | 2 | int:ZRSR2P1 | |
| Interaction | TSSK6 interactions | 2.71e-04 | 47 | 54 | 3 | int:TSSK6 | |
| Interaction | CA9 interactions | 2.73e-04 | 215 | 54 | 5 | int:CA9 | |
| Interaction | TANK interactions | 2.79e-04 | 216 | 54 | 5 | int:TANK | |
| Interaction | PCK1 interactions | 2.91e-04 | 119 | 54 | 4 | int:PCK1 | |
| Interaction | CLK1 interactions | 2.97e-04 | 219 | 54 | 5 | int:CLK1 | |
| Interaction | CLK3 interactions | 3.03e-04 | 220 | 54 | 5 | int:CLK3 | |
| Interaction | HLA-C interactions | 3.52e-04 | 353 | 54 | 6 | int:HLA-C | |
| Interaction | TMT1A interactions | 3.85e-04 | 359 | 54 | 6 | int:TMT1A | |
| Interaction | RAC2 interactions | 4.01e-04 | 674 | 54 | 8 | int:RAC2 | |
| Interaction | SSRP1 interactions | 4.47e-04 | 685 | 54 | 8 | int:SSRP1 | |
| Interaction | ADAM30 interactions | 4.56e-04 | 56 | 54 | 3 | int:ADAM30 | |
| Interaction | ASIC4 interactions | 4.57e-04 | 134 | 54 | 4 | int:ASIC4 | |
| Cytoband | 7q35 | 5.57e-07 | 55 | 54 | 4 | 7q35 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr7q35 | 1.17e-06 | 66 | 54 | 4 | chr7q35 | |
| Cytoband | 6p21.3 | 1.17e-05 | 250 | 54 | 5 | 6p21.3 | |
| GeneFamily | CTAGE family | 1.78e-08 | 15 | 36 | 4 | 907 | |
| GeneFamily | Histocompatibility complex|C1-set domain containing | 2.41e-08 | 44 | 36 | 5 | 588 | |
| GeneFamily | C1-set domain containing | 1.40e-06 | 42 | 36 | 4 | 591 | |
| GeneFamily | PHD finger proteins|NuRD complex | 2.51e-04 | 12 | 36 | 2 | 1305 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | 1.12e-03 | 25 | 36 | 2 | 775 | |
| GeneFamily | Ankyrin repeat domain containing | 1.32e-03 | 242 | 36 | 4 | 403 | |
| GeneFamily | Zinc fingers CCCH-type | 2.20e-03 | 35 | 36 | 2 | 73 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_ENDOTHELIAL_CELL_OF_LYMPHATIC_VESSEL_AGEING | 1.32e-10 | 16 | 54 | 5 | MM3766 | |
| Coexpression | HU_GENOTOXIC_DAMAGE_4HR | 3.30e-10 | 43 | 54 | 6 | MM1204 | |
| Coexpression | WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_DN | 3.49e-10 | 19 | 54 | 5 | MM797 | |
| Coexpression | MIKKELSEN_NPC_ICP_WITH_H3K27ME3 | 3.49e-10 | 19 | 54 | 5 | MM862 | |
| Coexpression | TABULA_MURIS_SENIS_BLADDER_LEUKOCYTE_AGEING | 4.65e-10 | 20 | 54 | 5 | MM3682 | |
| Coexpression | RUAN_RESPONSE_TO_TNF_UP | 6.09e-10 | 21 | 54 | 5 | MM651 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_PULMONARY_INTERSTITIAL_FIBROBLAST_AGEING | 1.27e-09 | 24 | 54 | 5 | MM3773 | |
| Coexpression | RUAN_RESPONSE_TO_TNF_TROGLITAZONE_UP | 1.58e-09 | 25 | 54 | 5 | MM672 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_MESANGIAL_CELL_AGEING | 5.01e-09 | 31 | 54 | 5 | MM3729 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_DISTAL_CONVOLUTED_TUBULE_EPITHELIAL_CELL_AGEING | 6.58e-09 | 124 | 54 | 7 | MM3726 | |
| Coexpression | PAL_PRMT5_TARGETS_DN | 9.51e-09 | 35 | 54 | 5 | MM674 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_CD8_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 1.68e-08 | 39 | 54 | 5 | MM3758 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_CORTEX_ARTERY_CELL_AGEING | 1.68e-08 | 39 | 54 | 5 | MM3725 | |
| Coexpression | HOWLIN_CITED1_TARGETS_1_UP | 2.17e-08 | 41 | 54 | 5 | MM710 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | IL10RA SMG1 UBXN4 LATS1 TRANK1 HLA-A HLA-B HLA-C SETD5 HLA-F HLA-H ANKRD49 TNRC6C MTDH THRAP3 ITPKB | 3.02e-08 | 1492 | 54 | 16 | M40023 |
| Coexpression | COATES_MACROPHAGE_M1_VS_M2_DN | 3.13e-08 | 90 | 54 | 6 | MM750 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_B_CELL_AGEING | 3.13e-08 | 90 | 54 | 6 | MM3756 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_TYPE_II_PNEUMOCYTE_AGEING | 3.14e-08 | 44 | 54 | 5 | MM3775 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_ENDOCARDIAL_CELL_AGEING | 3.95e-08 | 46 | 54 | 5 | MM3712 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_MATURE_ALPHA_BETA_T_CELL_AGEING | UBXN4 HLA-A HLA-B HLA-C SETD5 ZRSR2 PI4KA ZC3H13 HLA-F HLA-H MTDH | 3.96e-08 | 612 | 54 | 11 | MM3804 |
| Coexpression | BAUS_TFF2_TARGETS_UP | 5.46e-08 | 49 | 54 | 5 | MM1287 | |
| Coexpression | GSE6269_FLU_VS_STREP_PNEUMO_INF_PBMC_UP | 5.84e-08 | 170 | 54 | 7 | M5657 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_MEGAKARYOCYTE_ERYTHROID_PROGENITOR_CELL_AGEING | 6.06e-08 | 50 | 54 | 5 | MM3805 | |
| Coexpression | HOLLERN_MICROACINAR_BREAST_TUMOR_UP | 7.41e-08 | 52 | 54 | 5 | MM968 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_NAIVE_T_CELL_AGEING | 7.41e-08 | 52 | 54 | 5 | MM3808 | |
| Coexpression | TABULA_MURIS_SENIS_TONGUE_KERATINOCYTE_AGEING | 1.08e-07 | 56 | 54 | 5 | MM3852 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_SMOOTH_MUSCLE_CELL_AGEING | 1.18e-07 | 57 | 54 | 5 | MM3716 | |
| Coexpression | HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR | 1.29e-07 | 58 | 54 | 5 | MM661 | |
| Coexpression | TABULA_MURIS_SENIS_BRAIN_NON_MYELOID_INTERNEURON_AGEING | 1.41e-07 | 59 | 54 | 5 | MM3688 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_ENDOCARDIAL_CELL_AGEING | 1.41e-07 | 59 | 54 | 5 | MM3704 | |
| Coexpression | KUROKAWA_LIVER_CANCER_EARLY_RECURRENCE_DN | 1.65e-07 | 6 | 54 | 3 | M7182 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_VENTRICULAR_MYOCYTE_AGEING | 1.75e-07 | 120 | 54 | 6 | MM3710 | |
| Coexpression | YU_MYC_TARGETS_DN | 2.90e-07 | 68 | 54 | 5 | MM632 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_FIBROBLAST_OF_LUNG_AGEING | 3.82e-07 | 224 | 54 | 7 | MM3767 | |
| Coexpression | GAURNIER_PSMD4_TARGETS | 4.15e-07 | 73 | 54 | 5 | M11428 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_GRANULOCYTE_AGEING | 4.44e-07 | 74 | 54 | 5 | MM3796 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_B_CELL_AGEING | 4.70e-07 | 231 | 54 | 7 | MM3741 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_NK_CELL_AGEING | 4.75e-07 | 75 | 54 | 5 | MM3759 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_BRUSH_CELL_AGEING | 4.75e-07 | 75 | 54 | 5 | MM3718 | |
| Coexpression | TABULA_MURIS_SENIS_LIVER_HEPATOCYTE_AGEING | 5.81e-07 | 147 | 54 | 6 | MM3753 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_B_CELL_AGEING | 7.43e-07 | 82 | 54 | 5 | MM3777 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_MACROPHAGE_AGEING | 7.43e-07 | 82 | 54 | 5 | MM3858 | |
| Coexpression | WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP | 8.38e-07 | 84 | 54 | 5 | MM1049 | |
| Coexpression | MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 | 9.42e-07 | 86 | 54 | 5 | MM834 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_UP | 9.98e-07 | 87 | 54 | 5 | MM652 | |
| Coexpression | CASTELLANO_NRAS_TARGETS_UP | 1.06e-06 | 88 | 54 | 5 | MM1087 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_FENESTRATED_CELL_AGEING | 1.25e-06 | 91 | 54 | 5 | MM3720 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_SMOOTH_MUSCLE_CELL_AGEING | 1.32e-06 | 92 | 54 | 5 | MM3748 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_COLLECTING_DUCT_PRINCIPAL_CELL_AGEING | 1.38e-06 | 394 | 54 | 8 | MM3724 | |
| Coexpression | JACKSON_DNMT1_TARGETS_UP | 1.39e-06 | 93 | 54 | 5 | MM1185 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_NK_CELL_AGEING | 1.63e-06 | 96 | 54 | 5 | MM3834 | |
| Coexpression | TABULA_MURIS_SENIS_MAMMARY_GLAND_MACROPHAGE_AGEING | 1.71e-06 | 97 | 54 | 5 | MM3789 | |
| Coexpression | ZEMEK_IMMUNE_CHECKPOINT_BLOCKADE_OVARIAN_CANCER_OVERLAP_UP | 1.80e-06 | 98 | 54 | 5 | MM460 | |
| Coexpression | ZEMEK_IMMUNE_CHECKPOINT_BLOCKADE_OVARIAN_CANCER_RENCA_UP | 1.99e-06 | 100 | 54 | 5 | MM458 | |
| Coexpression | HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN | 2.05e-06 | 44 | 54 | 4 | MM805 | |
| Coexpression | WIELAND_UP_BY_HBV_INFECTION | 2.31e-06 | 103 | 54 | 5 | M11620 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN | 2.31e-06 | 103 | 54 | 5 | MM476 | |
| Coexpression | FOSTER_TOLERANT_MACROPHAGE_UP | 2.36e-06 | 187 | 54 | 6 | MM1034 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_PROMONOCYTE_AGEING | 2.42e-06 | 104 | 54 | 5 | MM3812 | |
| Coexpression | DURAND_STROMA_NS_UP | 2.92e-06 | 194 | 54 | 6 | MM962 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_MESENCHYMAL_STEM_CELL_AGEING | 3.10e-06 | 196 | 54 | 6 | MM3746 | |
| Coexpression | GSE3982_CENT_MEMORY_CD4_TCELL_VS_TH1_UP | 3.29e-06 | 198 | 54 | 6 | M5586 | |
| Coexpression | TABULA_MURIS_SENIS_SPLEEN_B_CELL_AGEING | 3.33e-06 | 111 | 54 | 5 | MM3831 | |
| Coexpression | GSE42021_CD24HI_VS_CD24LOW_TREG_THYMUS_DN | 3.49e-06 | 200 | 54 | 6 | M9588 | |
| Coexpression | GSE42021_TREG_VS_TCONV_PLN_UP | 3.49e-06 | 200 | 54 | 6 | M9572 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_ERYTHROBLAST_AGEING | 3.80e-06 | 203 | 54 | 6 | MM3795 | |
| Coexpression | ZHANG_UTERUS_C9_DENDRITIC_CELL | 3.80e-06 | 114 | 54 | 5 | MM16615 | |
| Coexpression | TABULA_MURIS_SENIS_MARROW_HEMATOPOIETIC_PRECURSOR_CELL_AGEING | 3.80e-06 | 114 | 54 | 5 | MM3799 | |
| Coexpression | BLANCO_MELO_BRONCHIAL_EPITHELIAL_CELLS_INFLUENZA_A_DEL_NS1_INFECTION_UP | 6.12e-06 | 644 | 54 | 9 | M34026 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_AND_AORTA_CARDIOMYOCYTE_AGEING | 6.21e-06 | 126 | 54 | 5 | MM3711 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_VALVE_CELL_AGEING | 6.21e-06 | 126 | 54 | 5 | MM3709 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_PODOCYTE_AGEING | 6.35e-06 | 222 | 54 | 6 | MM3733 | |
| Coexpression | GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN | 6.35e-06 | 222 | 54 | 6 | MM1132 | |
| Coexpression | MA_RAT_AGING_UP | 6.45e-06 | 127 | 54 | 5 | MM16096 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_FIBROBLAST_AGEING | 6.45e-06 | 127 | 54 | 5 | MM3856 | |
| Coexpression | TABULA_MURIS_SENIS_BROWN_ADIPOSE_TISSUE_ENDOTHELIAL_CELL_AGEING | 7.39e-06 | 228 | 54 | 6 | MM3676 | |
| Coexpression | MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3 | 7.79e-06 | 132 | 54 | 5 | MM841 | |
| Coexpression | FAN_EMBRYONIC_CTX_BRAIN_EFFECTOR_T_CELL | 7.79e-06 | 132 | 54 | 5 | M39046 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_SKELETAL_MUSCLE_SATELLITE_CELL_AGEING | 9.01e-06 | 136 | 54 | 5 | MM3747 | |
| Coexpression | ZHANG_UTERUS_C6_ENDOTHELIAL_PLVAP_HIGH_CELL | 9.33e-06 | 137 | 54 | 5 | MM16612 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING | 1.00e-05 | 685 | 54 | 9 | MM3782 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_ENDOTHELIAL_CELL_OF_CORONARY_ARTERY_AGEING | 1.04e-05 | 140 | 54 | 5 | MM3705 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_CD4_POSITIVE_ALPHA_BETA_T_CELL_AGEING | 1.11e-05 | 142 | 54 | 5 | MM3757 | |
| Coexpression | TABULA_MURIS_SENIS_AORTA_PROFESSIONAL_ANTIGEN_PRESENTING_CELL_AGEING | 1.15e-05 | 143 | 54 | 5 | MM3673 | |
| Coexpression | QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_POSITIVE | 1.19e-05 | 248 | 54 | 6 | M40874 | |
| Coexpression | TABULA_MURIS_SENIS_LIMB_MUSCLE_ENDOTHELIAL_CELL_AGEING | 1.23e-05 | 145 | 54 | 5 | MM3744 | |
| Coexpression | MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3 | 1.27e-05 | 146 | 54 | 5 | MM856 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_MONOCYTE_AGEING | 1.31e-05 | 147 | 54 | 5 | MM3707 | |
| Coexpression | FAN_EMBRYONIC_CTX_BIG_GROUPS_BRAIN_IMMUNE | 1.36e-05 | 148 | 54 | 5 | M39021 | |
| Coexpression | CUI_DEVELOPING_HEART_C9_B_T_CELL | 1.70e-05 | 155 | 54 | 5 | M39306 | |
| Coexpression | TABULA_MURIS_SENIS_LUNG_BRONCHIAL_SMOOTH_MUSCLE_CELL_AGEING | 1.75e-05 | 156 | 54 | 5 | MM3763 | |
| Coexpression | SANA_RESPONSE_TO_IFNG_UP | 1.85e-05 | 76 | 54 | 4 | M4551 | |
| Coexpression | TABULA_MURIS_SENIS_TONGUE_BASAL_CELL_OF_EPIDERMIS_AGEING | 1.86e-05 | 158 | 54 | 5 | MM3851 | |
| Coexpression | TABULA_MURIS_SENIS_BLADDER_BLADDER_UROTHELIAL_CELL_AGEING | 2.23e-05 | 164 | 54 | 5 | MM3680 | |
| Coexpression | TABULA_MURIS_SENIS_LIVER_ENDOTHELIAL_CELL_OF_HEPATIC_SINUSOID_AGEING | 2.32e-05 | 418 | 54 | 7 | MM3752 | |
| Coexpression | ZHANG_UTERUS_C8_NK_CELL | 2.50e-05 | 168 | 54 | 5 | MM16614 | |
| Coexpression | AFFAR_YY1_TARGETS_DN | 2.51e-05 | 283 | 54 | 6 | MM1157 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9 | 2.88e-05 | 85 | 54 | 4 | MM1279 | |
| Coexpression | KIM_LRRC3B_TARGETS | 3.23e-05 | 30 | 54 | 3 | M17363 | |
| Coexpression | TABULA_MURIS_SENIS_TRACHEA_T_CELL_AGEING | 3.45e-05 | 445 | 54 | 7 | MM3853 | |
| ToppCell | metastatic_Brain-T/NK_cells-Cytotoxic_CD8+_T|metastatic_Brain / Location, Cell class and cell subclass | 6.13e-08 | 171 | 54 | 6 | d3e1cc1b70256c4d01488d6b6130bbcae99bdeec | |
| ToppCell | metastatic_Brain-T/NK_cells-Exhausted_CD8+_T|T/NK_cells / Location, Cell class and cell subclass | 1.18e-07 | 191 | 54 | 6 | 2ffd40ebf1d63e61a97208ddcbeb6a86e409f9d8 | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-T_cells-CD8_Tmem|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.29e-07 | 194 | 54 | 6 | 13c3674d601c8a7355ce869de1af6401938c0037 | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_T_CD8-Trm/em_CD8|bone_marrow / Manually curated celltypes from each tissue | 1.33e-07 | 195 | 54 | 6 | ed4e2275dac47cc9fb9c381e3f80fed0ce50b074 | |
| ToppCell | tumor_Lung-T/NK_cells-CD8+/CD4+_Mixed_Th|tumor_Lung / Location, Cell class and cell subclass | 1.42e-07 | 197 | 54 | 6 | de26ca046038e34790cece24529a05d491e6f8ef | |
| ToppCell | COVID-19-lung|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.50e-07 | 199 | 54 | 6 | 155b03b859157013e9142e9248551369127d9204 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_4|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.15e-06 | 173 | 54 | 5 | b06d6e7acb7086bb99600b680cf404c0ef06b52c | |
| ToppCell | Severe-CD4+_T_activated|Severe / Disease group and Cell class | 2.41e-06 | 177 | 54 | 5 | a08f170f1143fcdd7d0842a54d9b807a4548f8b7 | |
| ToppCell | metastatic_Brain-T/NK_cells-CD8_low_T|metastatic_Brain / Location, Cell class and cell subclass | 2.62e-06 | 180 | 54 | 5 | 57eced5e314681857a853f7e6bb8b429f157e80e | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.69e-06 | 181 | 54 | 5 | 2f3d04d22d4ac016e61709ea5af3d48885c946c4 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.99e-06 | 185 | 54 | 5 | 487fa382232564f075960899d50afa0edae5d258 | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-T_cells-MAIT_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.99e-06 | 185 | 54 | 5 | 8314dc608bc837df3037e89afd9db39737374ebc | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-innate_lymphocytic|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.07e-06 | 186 | 54 | 5 | e84a0ba599935ca5e7af48e0fb0500e7ed195d55 | |
| ToppCell | COVID-19_Severe-CD4+_CTL|COVID-19_Severe / Disease condition and Cell class | 3.07e-06 | 186 | 54 | 5 | 728d81405fdcd137097433dd676b26519185e916 | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.07e-06 | 186 | 54 | 5 | 1590fe72badffc79f1d390deb3207116ac2281bb | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-Treg|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.07e-06 | 186 | 54 | 5 | 2a9daf96c2a47f1ed5421130f32f17bd33e644a7 | |
| ToppCell | tumor_Lung-T/NK_cells-Cytotoxic_CD8+_T|tumor_Lung / Location, Cell class and cell subclass | 3.15e-06 | 187 | 54 | 5 | 530839fb53bb285b22919fde6aa16ce1399615ef | |
| ToppCell | metastatic_Brain-T/NK_cells-Treg|metastatic_Brain / Location, Cell class and cell subclass | 3.15e-06 | 187 | 54 | 5 | 1b88e1399809c50a0156096d9c82b1d9e58bb720 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.24e-06 | 188 | 54 | 5 | 0501a8aa850bd2e347020abd1cac4d8075738189 | |
| ToppCell | BAL-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.41e-06 | 190 | 54 | 5 | 494fbab37305a7f92cddec75b291d42282555f5f | |
| ToppCell | BAL-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.41e-06 | 190 | 54 | 5 | 55df73c8b696967a925b1772631f6900eff0fa30 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD8-Trm/em_CD8|blood / Manually curated celltypes from each tissue | 3.41e-06 | 190 | 54 | 5 | e1f474dc36bf9eaf457b14a8761d287904754cdc | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-Exhausted_CD8+_T|metastatic_Lymph_Node / Location, Cell class and cell subclass | 3.41e-06 | 190 | 54 | 5 | cb4cf8ae2156c20b7978ae2e55aa605b4e90f455 | |
| ToppCell | control-Myeloid-Neutrophils_1|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 3.49e-06 | 191 | 54 | 5 | db1b3cd07d7d190155b2d14e82e1d124975fbd0b | |
| ToppCell | tumor_Lung-T/NK_cells-Exhausted_Tfh|tumor_Lung / Location, Cell class and cell subclass | 3.49e-06 | 191 | 54 | 5 | 3e259eba83f8159d1a1a96b98d0e867fe547c5e7 | |
| ToppCell | Fetal_29-31_weeks-Immune-T_lymphocyte|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 3.59e-06 | 192 | 54 | 5 | 69a2b04f03a1b82d067018379f7b8a116e954040 | |
| ToppCell | T/NK_cells-CD8+_Effector_T_cell|World / Lineage and Cell class | 3.68e-06 | 193 | 54 | 5 | 79fa0f482cd98642b1d38835cda98622f21e5bd0 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-CD8_low_T|T/NK_cells / Location, Cell class and cell subclass | 3.68e-06 | 193 | 54 | 5 | 48809047d3194aff225fc43c3d5152c20434fe62 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-CD8_low_T|normal_Lymph_Node / Location, Cell class and cell subclass | 3.68e-06 | 193 | 54 | 5 | e20ad6b62ad3aa386aa10b7a5d057d24a64ad386 | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-Cytotoxic_CD8+_T|metastatic_Lymph_Node / Location, Cell class and cell subclass | 3.77e-06 | 194 | 54 | 5 | 73c057b623829de793616d9d373a0018071d51d8 | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-T_cells-CD8_Tmem|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.77e-06 | 194 | 54 | 5 | 9344556b375fd9267652cdca57b2cbd50a878a1e | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-CD8_low_T|metastatic_Lymph_Node / Location, Cell class and cell subclass | 3.77e-06 | 194 | 54 | 5 | b0595b98332fee7936e455240bbefe72b79c98b8 | |
| ToppCell | tumor_Lung-T/NK_cells-Exhausted_CD8+_T|tumor_Lung / Location, Cell class and cell subclass | 3.77e-06 | 194 | 54 | 5 | 3fdcfd04174e39491d4f1e6276acc9d11e5a4345 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-CD4+_Th|normal_Lymph_Node / Location, Cell class and cell subclass | 3.77e-06 | 194 | 54 | 5 | 208b56b2a1f5494b74f9423f2bdc2eb6d6023fa9 | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-CD8_TEM|Multiple_Sclerosis / Disease, Lineage and Cell Type | 3.77e-06 | 194 | 54 | 5 | fa53f1aab2f5923e90f090e10e3560b583441dc4 | |
| ToppCell | control-Lymphocytic-CD8_T_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 3.87e-06 | 195 | 54 | 5 | 55b9052336cab3e769a126ecaeef267d8e7bcaa8 | |
| ToppCell | (1)_T_CD8_CTL|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 3.87e-06 | 195 | 54 | 5 | f582b854e5a4c52764aad5abe4e28ea77a7445f7 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.87e-06 | 195 | 54 | 5 | 6774c9f7fa54045aaa35fbd0695e43748da2b293 | |
| ToppCell | LA-09._Endothelium_I|World / Chamber and Cluster_Paper | 3.87e-06 | 195 | 54 | 5 | fc95457a298b5d0dab687d9ee7e225a7f7b9a0d4 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.87e-06 | 195 | 54 | 5 | 073593a7f668512d1fbbb49efb0c20b736c79ff8 | |
| ToppCell | Control-CD8+_Tem|Control / Disease condition and Cell class | 3.87e-06 | 195 | 54 | 5 | 7503b3e032f95b350a2782d28e4d412a8dc9ebcc | |
| ToppCell | COVID-19-Heart-EC_1|Heart / Disease (COVID-19 only), tissue and cell type | 3.87e-06 | 195 | 54 | 5 | 50a193475db1bb1e05b8590225a553688c372c14 | |
| ToppCell | (1)_T_CD8_activated|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 3.87e-06 | 195 | 54 | 5 | 2253590339b87692d350f9ea3d2aa851179967e1 | |
| ToppCell | T_cells-GZMK+_T_cells|T_cells / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 3.87e-06 | 195 | 54 | 5 | 003ea7ddec6c1c98d2f6470bb51ebd97450eb936 | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-Cytotoxic_CD8+_T|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 3.96e-06 | 196 | 54 | 5 | 6789c88a99cadfd8122ece4b736ba6783ae6e6f5 | |
| ToppCell | ILEUM-inflamed-(1)_T_cell-(1)_Cytotoxic_T_cells|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.96e-06 | 196 | 54 | 5 | a8217c8e27027c0444ce072fe194404345c34022 | |
| ToppCell | tumor_Lung-T/NK_cells|tumor_Lung / Location, Cell class and cell subclass | 3.96e-06 | 196 | 54 | 5 | 13396bb5f0dd0dce7219d3f7a1fc1fcb6b1ee134 | |
| ToppCell | ILEUM-inflamed-(1)_Cytotoxic_T_cells|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.96e-06 | 196 | 54 | 5 | 42d807605c6103fc80f038f4a351e89981533669 | |
| ToppCell | moderate-Lymphoid-Treg|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.96e-06 | 196 | 54 | 5 | 9152f4a8a27ff4ee28f231c5ad00eb2edd9ea6da | |
| ToppCell | CV-Moderate-1|Moderate / Virus stimulation, Condition and Cluster | 3.96e-06 | 196 | 54 | 5 | b50cfcd87c5b67806450cb8b3c6860ab97f6d3b1 | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_T_cell|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.96e-06 | 196 | 54 | 5 | 91902e135c05d1214d915c8d8e6037929c2501b8 | |
| ToppCell | B_cell_maturation-Memory_B_cell|B_cell_maturation / Lineage and Cell class | 3.96e-06 | 196 | 54 | 5 | 869ed6c83dfe0d874ea2bf2e358f54e5011e80e6 | |
| ToppCell | 18-Airway-Immune|Airway / Age, Tissue, Lineage and Cell class | 4.06e-06 | 197 | 54 | 5 | b28dd2aecb0658fbf48db06b675ed466d08d04eb | |
| ToppCell | COVID-19_Severe-Lymphoid_T/NK-CD8+_Tem|COVID-19_Severe / Disease group, lineage and cell class | 4.06e-06 | 197 | 54 | 5 | f0bac4d5c3160933ac3786cec8dadffb35d711ea | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1|390C / Donor, Lineage, Cell class and subclass (all cells) | 4.06e-06 | 197 | 54 | 5 | 4b480a527bc1d77e35b310287be8741e5f62b7f0 | |
| ToppCell | CV-Moderate-1|CV / Virus stimulation, Condition and Cluster | 4.06e-06 | 197 | 54 | 5 | e3d00d850b4d191f9592ef993c0eaadfe5710b5f | |
| ToppCell | severe-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 4.06e-06 | 197 | 54 | 5 | 57ebd552f10d6278623b52a3d484d4b91ae1d028 | |
| ToppCell | normal-na-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 4.06e-06 | 197 | 54 | 5 | b5b333e98753946793ceb45e2d85c25ef53568b4 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell|390C / Donor, Lineage, Cell class and subclass (all cells) | 4.06e-06 | 197 | 54 | 5 | e513d448385d5a8dbf68fb2b0892971cd841ae28 | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_memory_T_cell|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.06e-06 | 197 | 54 | 5 | 2e402a1d5a49c9943a165596dcc6fa89fcecb09c | |
| ToppCell | mild_COVID-19-CD8+_Tem|World / disease group, cell group and cell class (v2) | 4.06e-06 | 197 | 54 | 5 | 97fead264e986d922669a6006cbcec530c697df7 | |
| ToppCell | (1)_T_CD8_CytT|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 4.06e-06 | 197 | 54 | 5 | 804cec3b1839562dc027a5a2a1e015919bd31de7 | |
| ToppCell | LV-09._Endothelium_I|LV / Chamber and Cluster_Paper | 4.06e-06 | 197 | 54 | 5 | f9731d4d636e51b94a96805eee6afe9aedc175e3 | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-CD8_low_T|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 4.17e-06 | 198 | 54 | 5 | 8a21c183283fbc871aa729f8c42924b63018c345 | |
| ToppCell | Sepsis-URO-Lymphocyte-T/NK-gd_T|URO / Disease, condition lineage and cell class | 4.17e-06 | 198 | 54 | 5 | cb584f7754ef4e6d9ec7155022852f2d2676ab4f | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells|metastatic_Lymph_Node / Location, Cell class and cell subclass | 4.17e-06 | 198 | 54 | 5 | d62884fc2697f7ad1b0227d29fb9345a18ea3429 | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass | 4.17e-06 | 198 | 54 | 5 | fec6330dcea707f3ff65db736e9796d778de822c | |
| ToppCell | T_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 4.17e-06 | 198 | 54 | 5 | 1ca6cd8e75891fdfaddbb4a7342eec9ca4d11e5d | |
| ToppCell | moderate-Lymphoid-CTL|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 4.17e-06 | 198 | 54 | 5 | 0a868098b1ee4b28b2149ed766acb09e9c0ce14c | |
| ToppCell | CV-Mild-1|CV / Virus stimulation, Condition and Cluster | 4.17e-06 | 198 | 54 | 5 | 4b078714c49e7befb7b113d72485e712236d35fa | |
| ToppCell | mild_COVID-19-CD8+_Tem|mild_COVID-19 / disease group, cell group and cell class (v2) | 4.17e-06 | 198 | 54 | 5 | 12847340c36a6791d8bdcb81e731e2fdeec46326 | |
| ToppCell | mLN-B_cell-B_cell_memory|B_cell / Region, Cell class and subclass | 4.17e-06 | 198 | 54 | 5 | e2c63ca9f82f8524447e398b11a676b22d2f58ce | |
| ToppCell | 390C-Lymphocytic|390C / Donor, Lineage, Cell class and subclass (all cells) | 4.27e-06 | 199 | 54 | 5 | d66747762011459ef1d6d311d4a579f245a23be0 | |
| ToppCell | MS-IIF-Lymphocyte-T/NK-gd_T|IIF / Disease, condition lineage and cell class | 4.27e-06 | 199 | 54 | 5 | 2c0e981839c256d76fa049532c8d49f31ce9bfee | |
| ToppCell | (03)_KRT6B+-(2)_GFP_FOXI1|(03)_KRT6B+ / shred by cell type by condition | 4.27e-06 | 199 | 54 | 5 | c425e7975f492ed5cfcca022248adb627e1d27d4 | |
| ToppCell | COVID-19_Moderate|World / disease group, cell group and cell class | 4.27e-06 | 199 | 54 | 5 | 952fac67588ad5676f5939e3c7f8bac803c27064 | |
| ToppCell | Goblet_3|World / shred by cell class for nasal brushing | 4.27e-06 | 199 | 54 | 5 | 4229a17a3a6d8855655acc0a1c8704166f8e74c0 | |
| ToppCell | COVID-19_Mild-CD8+_Tem|COVID-19_Mild / Disease condition and Cell class | 4.27e-06 | 199 | 54 | 5 | 9016fbe5fe55e1ffa279ee8e8db3c93b5cf914d5 | |
| ToppCell | 10x_3'_v3-spleen_(10x_3'_v3)-lymphocytic-T_lymphocytic-naive_thymus-derived_CD8-positive,_alpha-beta_T_cell|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.27e-06 | 199 | 54 | 5 | db05c16d80f5a74bfa048a5c92917d312d26f769 | |
| ToppCell | COVID-19_Moderate-CD4+_CTL|World / disease group, cell group and cell class | 4.27e-06 | 199 | 54 | 5 | 12ea0346b4da3e8e2b3b2b3b3e9d4f4f104345a6 | |
| ToppCell | Caecum-T_cell-CD8_T|Caecum / Region, Cell class and subclass | 4.37e-06 | 200 | 54 | 5 | 8c0ced6cbfde40c2a9b54953c6fe93d83ad001d7 | |
| ToppCell | Caecum-(1)_T_cell-(10)_CD8_T|Caecum / shred on region, Cell_type, and subtype | 4.37e-06 | 200 | 54 | 5 | 4276d8e21a1bb3cf51f238455bb072a7600f9253 | |
| ToppCell | mLN-(1)_T_cell-(10)_CD8_T|mLN / shred on region, Cell_type, and subtype | 4.37e-06 | 200 | 54 | 5 | 6f02ba3a76e8aa3083efea9cb4ee587799c61fda | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-T/NK-CD8+_Tem|COVID-19_Severe / Disease, condition lineage and cell class | 4.37e-06 | 200 | 54 | 5 | 31859b8db7ea17e48b7b54e92f0d76aeb755e7ca | |
| ToppCell | MS-Multiple_Sclerosis-Lymphocyte-T/NK-CD8+_Tem|Multiple_Sclerosis / Disease, condition lineage and cell class | 4.37e-06 | 200 | 54 | 5 | cba63f8f2e7530e5539f7f5d93b3bcf5d693f6b9 | |
| ToppCell | mLN-T_cell-CD8_T|mLN / Region, Cell class and subclass | 4.37e-06 | 200 | 54 | 5 | a221213f9245297a5d6196564c1043f8c17eb857 | |
| ToppCell | mLN-T_cell-CD8_T|T_cell / Region, Cell class and subclass | 4.37e-06 | 200 | 54 | 5 | 650916c6d2bcf00315c7a21088cb63f37bf24346 | |
| ToppCell | (10)_CD8_T|World / shred on Cell_type and subtype | 4.93e-06 | 205 | 54 | 5 | 87c36989d0fc926f36d6b911ede068455f027177 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.56e-05 | 153 | 54 | 4 | ce7a23c687e9e7d83d244046de19c854caded09b | |
| ToppCell | metastatic_Brain-T/NK_cells-Naive_CD8+_T|metastatic_Brain / Location, Cell class and cell subclass | 3.84e-05 | 156 | 54 | 4 | 1dcb0b2d1c4b524e692d40e8403dbf7140af19b4 | |
| ToppCell | 10x3'2.3-week_12-13-Myeloid_DC-DC-DC3|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.35e-05 | 161 | 54 | 4 | 39030380e04f57f8e7de231577ec3177e1b6490d | |
| ToppCell | Multiple_Sclerosis-Lymphocyte-T_NK-CD4_CTL|Multiple_Sclerosis / Disease, Lineage and Cell Type | 4.45e-05 | 162 | 54 | 4 | d53de64df2511eddba79f899fc3f48b1b059923f | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Plasma_cells-IgM_plasma_cell|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.78e-05 | 165 | 54 | 4 | 6e8370b8e747d8ef44a2413a993291a3cd83a77c | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 5.49e-05 | 171 | 54 | 4 | 6be81c20f4e962b414afcedfe478dd59c510d1e1 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0|390C / Donor, Lineage, Cell class and subclass (all cells) | 5.49e-05 | 171 | 54 | 4 | d6d8ea45b443d95f64720c9bc07d324148f5b239 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_TBCC|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.75e-05 | 173 | 54 | 4 | d8b5e2c31fcc38998b7f8f5e9babb6fb5c0962da | |
| ToppCell | (6)_Endothelial_cells-(6)_Endothelial-E|(6)_Endothelial_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 5.88e-05 | 174 | 54 | 4 | 4a1b67ce5ea353b3f81f59fa57da07668146afca | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.01e-05 | 175 | 54 | 4 | da92eb8af0c7c65fed4a1d960708240f35dd997d | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.01e-05 | 175 | 54 | 4 | 2f43883d7c89f09b0579a390a7431f1f9b832582 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-CD8-positive,_alpha-beta_T_cell-CD8_T_cells-CD8_T_cells_L.1.1.0.4|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.14e-05 | 176 | 54 | 4 | ce85a13e10cf37f5cf38ca8b0bac6701b6d00ffd | |
| Computational | Genes in the cancer module 293. | 2.40e-08 | 12 | 30 | 4 | MODULE_293 | |
| Computational | Genes in the cancer module 143. | 4.84e-08 | 14 | 30 | 4 | MODULE_143 | |
| Computational | Neighborhood of PTPRC | 1.10e-06 | 68 | 30 | 5 | GNF2_PTPRC | |
| Computational | Neighborhood of CD48 | 1.68e-06 | 32 | 30 | 4 | GNF2_CD48 | |
| Computational | Neighborhood of INPP5D | 5.64e-06 | 43 | 30 | 4 | GNF2_INPP5D | |
| Computational | Neighborhood of HLA-C | 8.09e-06 | 47 | 30 | 4 | GNF2_HLA_C | |
| Computational | Neighborhood of PTPN6 | 8.09e-06 | 47 | 30 | 4 | GNF2_PTPN6 | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 1.04e-05 | 50 | 30 | 4 | GAVISH_3CA_MALIGNANT_METAPROGRAM_17_INTERFERON_MHC_II_1 | |
| Computational | Neighborhood of CD53 | 1.88e-05 | 58 | 30 | 4 | GNF2_CD53 | |
| Computational | Neighborhood of STAT6 | 6.41e-05 | 79 | 30 | 4 | GNF2_STAT6 | |
| Computational | Neighborhood of VAV1 | 1.32e-04 | 36 | 30 | 3 | GNF2_VAV1 | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 3.52e-04 | 50 | 30 | 3 | GAVISH_3CA_METAPROGRAM_EPITHELIAL_INTERFERON_MHC | |
| Computational | Genes in the cancer module 27. | 3.77e-04 | 355 | 30 | 6 | MODULE_27 | |
| Computational | Immune (defense) response. | 6.13e-04 | 142 | 30 | 4 | MODULE_223 | |
| Drug | AC1L1FCN | 5.31e-06 | 15 | 53 | 3 | CID000003178 | |
| Drug | tert-butyl acetate | 1.01e-05 | 58 | 53 | 4 | CID000010908 | |
| Drug | AC1NE3ZI | 2.02e-05 | 69 | 53 | 4 | CID004636205 | |
| Drug | A-26 | 2.64e-05 | 25 | 53 | 3 | CID000037120 | |
| Drug | PA-J | 3.18e-05 | 4 | 53 | 2 | CID000447261 | |
| Disease | graft-versus-host disease (implicated_via_orthology) | 2.34e-10 | 7 | 49 | 4 | DOID:0081267 (implicated_via_orthology) | |
| Disease | beta-2 microglobulin measurement | 7.03e-07 | 11 | 49 | 3 | EFO_0005197 | |
| Disease | – | 2.70e-06 | 2 | 49 | 2 | 608579 | |
| Disease | Susceptibility to severe cutaneous adverse reaction | 2.70e-06 | 2 | 49 | 2 | cv:C1840548 | |
| Disease | Carbamazepine response | 2.70e-06 | 2 | 49 | 2 | cv:CN077964 | |
| Disease | susceptibility to Mycobacterium tuberculosis infection measurement | 1.29e-05 | 86 | 49 | 4 | EFO_0008407 | |
| Disease | Drug-Induced Stevens Johnson Syndrome | 1.53e-05 | 29 | 49 | 3 | C1274933 | |
| Disease | Toxic Epidermal Necrolysis | 1.53e-05 | 29 | 49 | 3 | C0014518 | |
| Disease | Mycoplasma-Induced Stevens-Johnson Syndrome | 1.53e-05 | 29 | 49 | 3 | C3658301 | |
| Disease | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | 1.53e-05 | 29 | 49 | 3 | C3658302 | |
| Disease | Stevens-Johnson syndrome (is_implicated_in) | 1.62e-05 | 4 | 49 | 2 | DOID:0050426 (is_implicated_in) | |
| Disease | Stevens-Johnson Syndrome | 1.69e-05 | 30 | 49 | 3 | C0038325 | |
| Disease | allergic asthma (is_implicated_in) | 2.69e-05 | 5 | 49 | 2 | DOID:9415 (is_implicated_in) | |
| Disease | benign neoplasm (implicated_via_orthology) | 7.52e-05 | 8 | 49 | 2 | DOID:0060072 (implicated_via_orthology) | |
| Disease | Schizophrenia | 9.47e-05 | 883 | 49 | 8 | C0036341 | |
| Disease | Takayasu arteritis | 1.08e-04 | 148 | 49 | 4 | EFO_1001857 | |
| Disease | kidney cancer (implicated_via_orthology) | 1.47e-04 | 11 | 49 | 2 | DOID:263 (implicated_via_orthology) | |
| Disease | serum IgE measurement | 1.67e-04 | 64 | 49 | 3 | EFO_0004579 | |
| Disease | autism spectrum disorder, schizophrenia | 2.07e-04 | 327 | 49 | 5 | EFO_0003756, MONDO_0005090 | |
| Disease | Malignant Glioma | 2.18e-04 | 70 | 49 | 3 | C0555198 | |
| Disease | mixed gliomas | 2.18e-04 | 70 | 49 | 3 | C0259783 | |
| Disease | killer cell immunoglobulin-like receptor 2DS2 measurement | 2.80e-04 | 15 | 49 | 2 | EFO_0801746 | |
| Disease | phosphatidylcholine 38:3 measurement | 3.19e-04 | 16 | 49 | 2 | EFO_0010385 | |
| Disease | caudal anterior cingulate cortex volume measurement | 3.62e-04 | 17 | 49 | 2 | EFO_0010289 | |
| Disease | Glioma | 4.14e-04 | 87 | 49 | 3 | C0017638 | |
| Disease | gastric carcinoma | 4.42e-04 | 89 | 49 | 3 | EFO_0000178 | |
| Disease | Neurodevelopmental Disorders | 5.03e-04 | 93 | 49 | 3 | C1535926 | |
| Disease | COVID-19 (is_implicated_in) | 5.56e-04 | 21 | 49 | 2 | DOID:0080600 (is_implicated_in) | |
| Disease | susceptibility to pneumonia measurement | 5.69e-04 | 97 | 49 | 3 | EFO_0008410 | |
| Disease | Autistic Disorder | 9.27e-04 | 261 | 49 | 4 | C0004352 | |
| Disease | lymphocyte measurement | 9.80e-04 | 117 | 49 | 3 | EFO_0803546 | |
| Disease | tuberculosis (is_implicated_in) | 9.93e-04 | 28 | 49 | 2 | DOID:399 (is_implicated_in) | |
| Disease | basophil count | 1.21e-03 | 483 | 49 | 5 | EFO_0005090 | |
| Disease | cholesteryl ester measurement, low density lipoprotein cholesterol measurement | 1.21e-03 | 126 | 49 | 3 | EFO_0004611, EFO_0010351 | |
| Disease | sleep apnea measurement, obstructive sleep apnea | 1.38e-03 | 33 | 49 | 2 | EFO_0003918, EFO_0007817 | |
| Disease | excessive daytime sleepiness measurement | 1.38e-03 | 33 | 49 | 2 | EFO_0007875 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 1.38e-03 | 291 | 49 | 4 | EFO_0008317, EFO_0020946 | |
| Disease | Vasodilators used in cardiac diseases use measurement | 1.46e-03 | 34 | 49 | 2 | EFO_0009926 | |
| Disease | cerebrospinal fluid clusterin measurement | 1.55e-03 | 35 | 49 | 2 | EFO_0007657 | |
| Disease | age at menopause | 1.59e-03 | 302 | 49 | 4 | EFO_0004704 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QIEWQNSTIDSEDGE | 1061 | Q9H2P0 | |
| DNLELEVNSQWENGA | 291 | Q8IX94 | |
| DNLELEVNSQWENGA | 291 | Q86UF2 | |
| DNLELEVNSQWENGA | 291 | P0CG41 | |
| DNLELEVNSQWENGA | 291 | A4D2H0 | |
| QEDQEWQDELSDNQS | 1356 | Q8TDI0 | |
| ESGVDVNSQNEVNGW | 31 | Q6AI12 | |
| NWASELAQEQESERE | 676 | O60312 | |
| DVSGTQGNQVEQDTW | 796 | Q6ZP01 | |
| LTWQRDGEEQTQDTE | 236 | P30511 | |
| WQRDGEDQTQDTELV | 241 | P01893 | |
| EGSDSEAAQWADQEQ | 546 | Q9UJX3 | |
| TRDEGGNQQDEAITW | 221 | Q6NYC1 | |
| DNEEENVNDTLNGWY | 1051 | O95835 | |
| GTAEIDLNDWRNNTE | 1486 | Q76N89 | |
| QTAEEAWDRNLDING | 131 | P0CG22 | |
| NDDNEWERIQGSTFS | 361 | P98073 | |
| WQRDGEDQTQDTELV | 241 | P10321 | |
| DVNSNGIEWSNENDR | 911 | Q13370 | |
| ELDQAGENSVANWRS | 1516 | P42356 | |
| TPNWSEESEEENDQQ | 161 | Q96RT8 | |
| TWEQQVGSNSRGQDD | 386 | Q13651 | |
| TQSLWVGNSDEDEEQ | 41 | Q8WVL7 | |
| GEEESQNSDEWQLQG | 101 | Q9P215 | |
| WQLQGGTSAENEESD | 111 | Q9P215 | |
| WQRDGEDQTQDTELV | 241 | P01889 | |
| ASWAQEDQQDADEDR | 131 | Q8NB16 | |
| ENLVNDVSDEAWNER | 436 | Q9BTT6 | |
| ENRNNQGTVNWSVDD | 66 | P52292 | |
| EQEQFDDWSRDIQSG | 531 | Q8NCM8 | |
| SENWRIFREEQNGED | 201 | Q6Y7W6 | |
| STSENQTEWNARDDE | 681 | Q9HC77 | |
| WQRDGEDQTQDTELV | 241 | P04439 | |
| WQDELAQQAEEGSAR | 6 | Q86UE4 | |
| TNDEGRQGDDEQSDW | 236 | Q9NWQ4 | |
| NDGSQEDRDWQDDQS | 1346 | Q14839 | |
| EDRDWQDDQSDNQSD | 1351 | Q14839 | |
| TQDNGDHIWTNGENE | 421 | Q8NG08 | |
| QEQVREEVSWDTENS | 426 | P28827 | |
| EQNWEAVDGSQTETE | 496 | P11717 | |
| EEGDVWNNAASQEST | 896 | Q9HCJ0 | |
| SEDQWAVQEEIDNGS | 331 | Q14DG7 | |
| VQSEGTWESQRQDSD | 526 | P27987 | |
| VAVSQENDEENEERW | 36 | Q96BP3 | |
| NPDQDVSQWTTADND | 956 | Q96Q15 | |
| QNLDENTTEGWENRI | 196 | Q9C0A6 | |
| WENEDDTAISRRQDN | 246 | Q5VX52 | |
| SNNDFQKRNREEEWD | 856 | Q9Y2W1 | |
| GENTAQWRSQENEED | 41 | P49810 | |
| NEDAENWENKARQSE | 421 | Q9BZW7 | |
| GNDDQDDWSTQEIEA | 766 | O15050 | |
| HVGENDENQDRGNWS | 26 | Q9UN76 | |
| RLRTQDDGEDENNTW | 486 | Q92575 | |
| DDGEDENNTWNGNST | 491 | Q92575 | |
| DQAENELENGTTWQN | 141 | Q15696 | |
| NVEWETNRDDSDNGD | 141 | Q5T200 | |
| LGNSWQTDQDEDQEC | 1316 | Q9Y493 | |
| VENRANVNQQDNEGW | 111 | O60237 |